News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY)'s Avastin Disappoints Against Ovarian Cancer


12/29/2011 10:02:44 AM

Two studies found that Genentech's cancer drug Avastin failed to prolong life on patients, but kept their disease from worsening for a time, the Washington Post reports.

The two studies released Thursday showed the drug could slow the growth of ovarian cancer when added to chemotherapy, news that was welcomed by patient advocates, who point to the lack of new treatments for the disease.

With the mixed results, though, Genentech said it was unlikely at this time to seek Food and Drug Administration approval of Avastin for ovarian cancer.


Read at USA Today
Read at CBS News
Read at Time
Read at Washington Post
Read at San Francisco Business Times


comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES